Trial Profile
A Phase 2, Open-Label Study With Orally Administered CVM-1118 and Sorafenib in Subjects With Advanced Hepatocellular Carcinoma
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 12 Jan 2023
Price :
$35
*
At a glance
- Drugs Foslinanib (Primary) ; Sorafenib (Primary)
- Indications Liver cancer
- Focus Therapeutic Use
- Sponsors TaiRx
- 06 Jan 2023 Status changed from active, no longer recruiting to discontinued.
- 25 Nov 2021 Planned End Date changed from 1 Aug 2022 to 1 Mar 2022.
- 25 Nov 2021 Planned primary completion date changed from 1 May 2022 to 1 Dec 2021.